Altogether, the epigenetic alteration of FGFR1 represents a candidate biomarker of resistance to cetuximab and further studies are critical to identify combination therapies for HNSCC patients that develop acquired cetuximab resistance. This evidence concerns the gene FGFR1 and head and neck squamous cell carcinoma.